Induction of cardiac fibrosis by transforming growth factor-β1

Molecular Genetics and Metabolism

Volumn 71, Issue 1-2, 2000, Pages 418-435

  Lijnen, P J ^a   Petrov, V V ^a   Fagard, R H ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

Author keywords

Collagen; Extracellular matrix proteins; Fibroblasts; Gene expression; Myocardial fibrosis; Transforming growth factor 1

Indexed keywords

ANGIOTENSIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ISOPRENALINE; MESSENGER RNA; NORADRENALIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

COLLAGEN SYNTHESIS; FIBROBLAST CULTURE; GENE EXPRESSION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; SHORT SURVEY;

EID: 0033813219     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2000.3032     Document Type: Article

References (167)

1. The TGF-β superfamily: New members, new receptors and new genetic tests of function in different organisms
2. The TGF-β family and its composite receptors
3. The transforming growth factor-betas
4. Regulation and interactions of transforming growth factor-β with cardiovascular cells: Implications for development and disease
5. 1 expression in rat ventricular myocytes
6. 1 in acute myocardial infarction in rats
7. Regulation of cardiovascular collagen synthesis by mechanical load
8. Transforming growth factor-β in disease: The dark side of tissue repair
9. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
10. Autoinduction of mRNA and protein expression for transforming growth factor-βs in cultured cardiac cells
11. Transforming growth factor-β in tissue fibrosis
12. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis
13. The transforming growth factor-β family
14. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7
15. Intron-exon structure of human transforming growth factor-beta precursor gene
16. TGF-β signal transduction
17. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium
18. An activated form of transforming growth factor-β is produced by coculture of endothelial cells and pericytes
19. Growth factors in the regulation of pericellular proteolysis - A review
20. 1 by plasmin
21. Autocrine regulation of TGF-β expression in adult cardiomyocytes
22. Transforming growth factor-beta receptors: Role in physiology and disease
23. TGF-beta receptors: Structure and function
24. Determination of type I receptor specificity by the type II receptors for TGF-β or activin
25. Expression cloning and characterization of the TGF-β type III receptor
26. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: Mapping of ligand binding and GAG attachment sites
27. A transcriptional partner for MAD proteins in TGF-β signalling
28. 1 signalling from cell membrane to nucleus through SMAD proteins
29. TGF-beta signaling through the Smad pathway
30. 1 in the negative growth control of breast cancer cells
31. Transforming growth factor beta activation of p44 mapk in proliferating cultures of epithelial cells
32. 1 on gene expression
33. Two different signal transduction pathways can be activated by transforming growth factor beta-1 epithelial cells
34. 1 and repair in the infarcted heart
35. 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy
36. Coordinate TGF-beta receptor gene expression during rat heart development
37. Role of transforming growth factor-β in maintenance of function of cultured neonatal cardiac myocytes
38. 1 in mitochondria of murine heart and liver
39. 1 or bone morphogenetic protein
40. 1 in heart development
41. Cellular origin and distribution of transforming growth factor-beta in the normal rat myocardium
42. Hyperthermia induces expression of transforming growth factor-betas in rat cardiac cells in vitro and in vivo
43. 1 in adult rat cardiac fibroblasts
44. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns
45. 1 fibronectin and collagen
46. 1 in infarcted rat heart
47. 1 in normal heart and in myocardial infarction
48. Elevation of expression of Smads 2, 3 and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing
49. 1 in rat cardiac fibroblasts, myocytes and smooth muscle cells
50. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats
51. Regulation of collagenase gene expression in cardiac fibroblasts by transforming growth factor-β
52. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts
53. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts
54. Angiotensin II-induced trans-activation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-β synthesis via transcriptional and posttranscriptional mechanisms
55. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: Marked upregulation of genes encoding extracellular matrix components
56. 1 expression
57. 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats
58. 3 in cardiomyocytes during pressure overload-induced hypertrophy
59. Growth factor properties and biochemical characterization of collagens synthesized by adult rat heart fibroblasts in culture
60. Role of extracellular matrix proteins in heart function
61. 2 chains of type IV collagen in the infarct zone of rat myocardial infarction
62. Relation of structure to function of the tissues of the wall of blood vessels
63. Collagen remodeling of the pressure-over-loaded, hypertrophied nonhuman primate myocardium
64. Collagen: Scaffold for repair and execution
65. Monitoring fibrillar collagen turnover in hypertensive heart disease
66. Circulatory C-terminal propeptide of type I procollagen is cleared mainly via a mannose receptor in the liver endothelial cells
67. Biliary excretion of procollagen type III peptide in healthy humans and in patients with alcoholic cirrhosis of the liver
68. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis
69. The amino-terminal propeptide of type III collagen provides new information on prognosis after acute myocardial infarction
70. Serum amino-terminal type III procollagen peptide reflects repair after acute myocardial infarction
71. Collagen scar formation after acute myocardial infarction
72. Collagen degradation in the heart
73. Radio-immunoassay for the pyridoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
74. Connective tissue and repair in the heart
75. Connective tissue: Metabolic entity?
76. Inflammatory and vascular basis of connective tissue disease
77. Reactive and reparative fibrillar collagen remodeling in the hypertrophied rat left ventricle: Two experimental models of myocardial fibrosis
78. Regulation of collagen degradation in the rat myocardium after infarction
79. Collagen remodeling after myocardial infarcton in the rat heart
80. Myofibroblasts from diverse pathologic settings in their content of actin isoforms and intermediate filament proteins
81. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion
82. Bradykinin receptor and tissue ACE binding in myocardial fibrosis: Response to chronic angiotensin II or aldosterone administration in rats
83. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis
84. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
85. Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of fenotypic modulation
86. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing
87. The α-smooth muscle actin-positive cells in healing human myocardial scars
88. Contractile cells in rat myocardial scar tissue
89. Dupuytren's contracture: Fibroblast contraction
90. Phenotypic and functional features of myofibroblasts in sheep fetal wounds
91. 1 induces a-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts
92. Transforming growth factor beta-1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro
93. 1 in quiescent human breast gland fibroblasts
94. 1
95. 1 induces lens cells to accumulate α-smooth muscle actin, a marker for subcapsular cataracts
96. Induction of α-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes
97. 1 promotes contraction of collagen gel by bovine corneal fibroblasts through differentiation of myofibroblasts
98. 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors
99. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: Specific effect of transforming growth factor-β
100. 1 induced differentiation of cardiac fibroblasts to myofibroblasts is accompanied by an increase in angiotensin converting enzyme activity
101. Myofibroblasts and their role in lung collagen expression during pulmonary fibrosis: A combined immunohistochemical and in situ hybridization
102. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts
103. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor
104. Collagen synthesis in fibroblasts from keloid lesions and their responses to transforming growth factor-beta
105. Transforming growth factor-beta: Biological function and chemical structure
106. Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors
107. Mechanical load enhances the stimulatory effect of serum growth factors on cardiac fibroblast procollagen synthesis
108. 1 (I) collagen promoter via transforming growth factor-beta activation element
109. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin and type I procollagen by transforming growth factor-β
110. Increase in the expression of biglycan mRNA expression co-localized closely with that of type I collagen mRNA in the infarct zone after experimentally-induced myocardial infarction in rats
111. Non-uniform influence of transforming growth factor-beta on the biosynthesis of different forms of small chondroitin sulphate/dermatan sulphate proteoglycan
112. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts
113. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
114. 1 on myocardial stunning in the intact dog
115. Mediation of cardioprotection by transforming growth factor-β
116. Workshop Report. Cardio-reparation and the concept of modulating cardiovascular structure and function
117. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β on myocardial stunning in the intact dog
118. 1 induces prolonged severe fibrosis in rat lung
119. 1 receptor anti-sense gene therapy in hypertensive rat offspring
120. Reversal of hypertension by angiotensin II type I receptor antisense gene therapy in the adult SHR
121. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia
122. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death
123. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease
124. Early-onset multifocal inflammation in the transforming growth factor beta-1 null mouse is lymphocyte mediated
125. 1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis
126. 1 transgene in the heart
127. 1 on intracardiac grafts promotes vascular endothelial cell DNA synthesis
128. 1 heterozygous mice
129. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat
130. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats
131. Tissue-specific regulation of growth factors and clustering by angiotensin II
132. 1 in cardiac fibroblasts and myofibroblasts
133. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
134. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment
135. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis
136. Quantitation of isoprenaline-induced changes in the ventricular myocardium
137. Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment
138. The fibrillar nature and structure of isoproterenol-induced myocardial fibrosis in the rat
139. 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: Effects of inhibition of the renin-angiotensin system
140. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy
141. Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents
142. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat
143. Left ventricular hypertrophy and risk of cardiac failure: Insights from the Framingham study
144. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
145. Prevention of salt-dependent remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine
146. Efficient inhibition of the development of cardiac remodeling by a long-acting antagonist amlodipine
147. Myocardial fibrosis associated with aldosterone or angiotensin II administration: Attenuation by calcium channel blockade
148. Transforming growth factor β-induced collagen synthesis during calcium channel blockade in cardiac fibroblasts
149. Differential remodeling of the left and right heart after norepinephrine treatment in rats: Studies on cytokines and collagen
150. Cardiac angiotensin II receptor is increased in rats with cardiac remodeling induced by long-term blockade of nitric oxide synthesis
151. Chronic blockade of NO synthase activity induces a proinflamamtory phenotype in the arterial wall: Prevention by angiotensin II antagonism
152. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats
153. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats
154. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade
155. Inhibition of nitric oxide synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels
156. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats
157. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure
158. Molecular cloning and characterization of human TIMP-4
159. Ventricular remodeling in heart failure: The role of myocardial collagen
160. Role of extracellular matrix metalloproteinases in cardiac remodeling
161. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells
162. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium
163. 1 suppresses intimal hyperplasia in a rat model
164. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
165. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor-beta
166. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease